Qilin, the ransomware group behind a string of healthcare attacks, has listed pharmaceutical development firm Crystal Pharmatech on its leak site. Trackers flagged the claim on August 6, with HookPhish, GalaxyWarden, and ransomware.live all carrying the listing.
Crystal Pharmatech is a contract research and development organization focused on crystal engineering, solid-state chemistry, and drug formulation for pharmaceutical companies. The firm helps drug developers design stable, manufacturable formulations, which means its files can carry formulation data, analytical results, and client-specific research tied to pipeline products.
The listing is unconfirmed, and no data samples have been posted. Qilin has repeatedly targeted healthcare and pharma in 2026, including hospital networks and medical vendors, and its playbook typically pairs encryption with data theft for extortion.
For pharma and biotech organizations, the incident is a reminder that contract development partners hold intellectual property as valuable as any clinical record. Companies working with CDMOs should confirm that vendor agreements require breach notification, encryption of research data, and timely disclosure of extortion events that touch their projects.
